Canadian Agency Recommends Enspryng Costs Be Reimbursed
Enspryng (satralizumab), a therapy for adolescents and adults with neuromyelitis optica spectrum disorder (NMOSD), has been recommended for reimbursement through Canada’s public drug plans, if certain conditions are met. Among the conditions established by the Canadian Drug…